Generics BulletinGedeon Richter feels its General Medicines division is “unfairly neglected” and “deserves a lot more attention and credit than we tend to give it,” as the Hungarian firm looks to add to reported 12% f
Generics BulletinAdalvo and Gedeon Richter have announced a global co-development deal for injectable semaglutide, that will see the firms pursue launches around the world in the potentially lucrative GLP-1 obesity ma
Generics BulletinFour biosimilars sponsors – Biocon Biologics, Gedeon Richter, Mabxience and Zentiva – have each received dual positive opinions from the European Medicines Agency’s Committee for Medicinal Products fo
Pink SheetThe European Medicines Agency has started reviewing for potential pan-EU marketing authorization 15 new drugs, including Novo Nordisk’s semaglutide for the treatment of non-cirrhotic metabolic dysfunc